Emergent Biosolutions Inc (NYSE:EBS) Receives $92.57 Consensus PT from Brokerages

Emergent Biosolutions Inc (NYSE:EBS) has been assigned an average rating of “Hold” from the ten research firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $92.57.

EBS has been the subject of a number of recent analyst reports. Chardan Capital boosted their price objective on shares of Emergent Biosolutions from $86.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research note on Monday. They set a “neutral” rating on the stock. Guggenheim reduced their price target on shares of Emergent Biosolutions from $101.00 to $87.00 and set a “buy” rating for the company in a research note on Monday, June 8th. ValuEngine downgraded shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Cantor Fitzgerald lifted their target price on shares of Emergent Biosolutions from $85.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th.

In related news, major shareholder Fuad El-Hibri sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $102.73, for a total transaction of $4,109,200.00. Following the completion of the transaction, the insider now directly owns 1,209,523 shares in the company, valued at approximately $124,254,297.79. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Zsolt Harsanyi sold 6,609 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $133.71, for a total transaction of $883,689.39. Following the completion of the sale, the director now directly owns 24,579 shares of the company’s stock, valued at $3,286,458.09. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,027 shares of company stock worth $8,898,199. 14.10% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Emergent Biosolutions by 3.4% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,101 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 134 shares in the last quarter. Chatham Capital Group Inc. lifted its holdings in shares of Emergent Biosolutions by 0.5% in the second quarter. Chatham Capital Group Inc. now owns 26,277 shares of the biopharmaceutical company’s stock worth $2,078,000 after buying an additional 134 shares in the last quarter. M&T Bank Corp boosted its position in shares of Emergent Biosolutions by 0.9% during the first quarter. M&T Bank Corp now owns 23,921 shares of the biopharmaceutical company’s stock worth $1,384,000 after acquiring an additional 208 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in Emergent Biosolutions by 112.7% during the first quarter. Rockefeller Capital Management L.P. now owns 453 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 240 shares in the last quarter. Finally, Huntington National Bank increased its holdings in Emergent Biosolutions by 22.8% in the 2nd quarter. Huntington National Bank now owns 1,307 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 243 shares during the last quarter.

NYSE EBS traded down $0.42 during trading hours on Wednesday, reaching $102.34. 437,564 shares of the company’s stock traded hands, compared to its average volume of 657,756. The firm has a market cap of $5.42 billion, a PE ratio of 31.88 and a beta of 1.42. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.71 and a quick ratio of 1.91. Emergent Biosolutions has a 52-week low of $46.37 and a 52-week high of $137.61. The firm has a 50-day simple moving average of $115.26 and a 200 day simple moving average of $83.91.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.98 earnings per share for the quarter, topping the consensus estimate of $0.53 by $1.45. Emergent Biosolutions had a return on equity of 22.92% and a net margin of 13.52%. The company had revenue of $394.70 million for the quarter. Sell-side analysts forecast that Emergent Biosolutions will post 6.67 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.